Roche, Sanofi Double Down On Post-Coronavirus China With Oncology Alliances
Attractions As A Rising Innovator
In a bid widely seen as a move to double down on their “in China for China” strategy, Sanofi and Roche have formed new drug development alliances with local innovative players potentially worth billions.
You may also be interested in...
The latest big pharma vote of confidence in both the China market and R&D capabilities comes amid continuing standoffs with the US over a flurry of issues including the coronavirus, national security and trade, but as the pandemic seemingly recedes in China.
During the “Road to Commercialization” panel session during EBD/Informa Connect's recent annual ChinaBio partnering event, senior executives from top Chinese biotechs along with a leading contract manufacturing organization and venture fund shared views on biologics commercialization in China. Partnerships to accelerate the process, as well as the future commercial direction of novel biologics in their fastest-growing market worldwide, were also discussed.
Lilly is acquiring exclusive global rights to a Chinese domestically developed immuno-oncology drug in one of the year’s biggest commercial deals in the country.